● Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Condition: Multiple Myeloma (MM) · Sponsor: European Myeloma Network B.V.

PhasePhase 2

Planned participants150

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trial Office · +390110243236 · amministrazione@emnresearch.it

Always discuss trial participation with your own doctor first.

Locations (29)

IT-Ascoli Piceno-Ospedale Mazzoni [01-016]	Ascoli Piceno, Italy	Recruiting
IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018]	Bari, Italy	Not Yet Recruiting
IT-Bergamo-A.O. Papa Giovanni XXIII [01-003]	Bergamo, Italy	Not Yet Recruiting
IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004]	Bologna, Italy	Not Yet Recruiting
IT-Bolzano-Ospedale di Bolzano - Azienda Sanitaria dell'Alto Adige [01-021]	Bolzano, Italy	Not Yet Recruiting
IT-Como-Ospedale Classificato Valduce [01-104]	Como, Italy	Recruiting
IT-Milano-Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico [01-039]	Milan, Italy	Not Yet Recruiting
IT-Milano-Ospedale S. Carlo Borromeo [01-105]	Milan, Italy	Recruiting
IT-Novara-A.O.U. Maggiore della Carità [01-010]	Novara, Italy	Recruiting
IT-Pescara-Azienda USL di Pescara P.O. dello Spirito Santo [01-053]	Pescara, Italy	Recruiting
IT-Roma-ASL Roma 1 [01-101]	Roma, Italy	Not Yet Recruiting
IT-Roma-Policlinico Umberto I - Università 'Sapienza' [01-013]	Roma, Italy	Not Yet Recruiting

+ 17 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07107529